Vaxxas

Vaxxas is a private, clinical-stage biotech founded in 2011, pioneering a needle-free vaccine delivery platform. Its core technology, the HD-MAP patch, uses thousands of micro-projections to deliver vaccine to the skin, aiming to improve immune response, enable thermostable formulations, and simplify administration. The company has validated its platform in human studies, secured significant partnerships with entities like Merck, BARDA, and CEPI, and is advancing a pipeline focused on influenza and other vaccines towards commercialization.

High-Density Microarray Patch (HD-MAP): A needle-free patch with thousands of micro-projections that deliver vaccine to the immune-rich skin layer. Includes proprietary dry-coating technology for thermostable formulations and a reusable applicator device.

Vaxxas competes in the needle-free vaccine delivery space against other microneedle patch developers (e.g., Micron Biomedical, Verndari) and legacy technologies like jet injectors. Its primary competitive advantages are its high-density array design for efficient skin delivery, validated dry-coating process for thermostability, and established partnerships with major pharmaceutical and global health entities.